Myriad's BRCA Gene Patents Struck Down In Court; Are Biotech's Foundations Shaking?
This article was originally published in The Pink Sheet Daily
Executive Summary
Judge finds that isolated DNA is not different from that in the body and thus unpatentable; Myriad says its products are covered by other patents.
You may also be interested in...
Gene Patents: Supreme Court Could Be Swayed By Impact On Research
The outcome of ACLU’s suit challenging Myriad Genetics’ BRCA cancer genes is crucial for the biotech industry as it could prevent companies from getting patents on therapeutics that utilize DNA and other isolated molecules.
Myriad Gene Patent Fight: Biotech And Pharma Are Ringside For Round Two
Industry wants a narrow decision as the Biotechnology Industry Organization urges the Federal Circuit to protect composition of matter claims in reconsidering the ACLU’s suit against Myriad; Lilly calls for the court to create a bright patent-eligibility line.
Supreme Court To Consider Prometheus Patents On Method Of Calibrating Drug Dosage
Mayo contends Prometheus patents cover a natural phenomenon.